Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Search: (WFRF:(Portelius Erik 1977)) srt2:(2010-2014) > Safety and tolerabi...

Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.

Coric, Vladimir (author)

van Dyck, Christopher H (author)

Salloway, Stephen (author)

Andreasen, Niels (author): Karolinska Institutet

Brody, Mark (author)

Richter, Ralph W (author)

Soininen, Hilkka (author)

Thein, Stephen (author)

Shiovitz, Thomas (author)

Pilcher, Gary (author)

Colby, Susan (author)

Rollin, Linda (author)

Dockens, Randy (author)

Pachai, Chahin (author)

Portelius, Erik, 1977 (author): Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry

Andreasson, Ulf, 1968 (author): Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry

Blennow, Kaj, 1958 (author): Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry

Soares, Holly (author)

Albright, Charles (author)

Feldman, Howard H (author)

Berman, Robert M (author)

show less...

(creator_code:org_t)

American Medical Association (AMA), 2012
2012
English.
In: Archives of neurology. - : American Medical Association (AMA). - 1538-3687 .- 0003-9942. ; 69:11, s. 1430-40

Related links:: https://jamanetwork....; show more...; https://gup.ub.gu.se...; https://doi.org/10.1...; http://kipublication...; show less...

Journal article (peer-reviewed)

Abstract Subject headings

To assess the safety, tolerability, and pharmacokinetic and pharmacodynamic effects of the -secretase inhibitor avagacestat in patients with mild to moderate Alzheimer disease (AD).

Subject headings

MEDICIN OCH HÄLSOVETENSKAP -- Medicinska och farmaceutiska grundvetenskaper -- Neurovetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES -- Basic Medicine -- Neurosciences (hsv//eng)

Keyword

Activities of Daily Living
Aged
Aged
80 and over
Alzheimer Disease
diagnosis
drug therapy
metabolism
psychology
Amyloid Precursor Protein Secretases
antagonists & inhibitors
Amyloid beta-Peptides
cerebrospinal fluid
Body Weight
drug effects
Dose-Response Relationship
Drug
Double-Blind Method
Enzyme Inhibitors
blood
therapeutic use
Female
Humans
Immunoprecipitation
International Cooperation
Magnetic Resonance Imaging
Male
Mass Spectrometry
Middle Aged
Neuropsychological Tests
Outcome Assessment (Health Care)
Oxadiazoles
blood
therapeutic use
Psychiatric Status Rating Scales
Sulfonamides
blood
therapeutic use
Time Factors
tau Proteins
cerebrospinal fluid

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

Archives of neurology (Search for host publication in LIBRIS)

To the university's database

Find more in SwePub

About the subject

MEDICAL AND HEALTH SCIENCES: MEDICAL AND HEAL ...; and Basic Medicine; and Neurosciences

Articles in the publication: Archives of neur ...

By the university: University of Gothenburg; Karolinska Institutet

Search outside SwePub

Extend your search to:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se